US Patent 11389541 Sustained delivery of angiopoetin-like 3 polypeptides
Patent 11389541 was granted and assigned to Novartis on July, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 16 Oct, 2023
Golden AI
Edits made to:
Infobox (+8 properties)
Infobox
Patent Inventor Names
Cameron Chuck-munn Lee0
Christopher M. Adams0
Cornelia Jutta Forster0
Edward Charles Hall0
Jean-Baptiste Georges Armand Langlois0
Myriam April0
Nicole Gerwin0
Tanzina Fazal0
Edits on 29 Apr, 2023
Golden AI
Infobox
Edits on 28 Apr, 2023
Golden AI
Infobox
Edits on 31 Mar, 2023
Golden AI
Infobox
Edits on 26 Sep, 2022
Golden AI
Infobox
Golden AI
Infobox
Edits on 23 Sep, 2022
Golden AI
Infobox
Edits on 20 Jul, 2022
Golden AI
Edits made to:
Infobox (+23 properties)
Article (+399 characters)
US Patent 11389541 Sustained delivery of angiopoetin-like 3 polypeptides
Article
Described herein are drug delivery systems for delivering biologically active agents comprising primary or secondary amines, or a ring nitrogen atom of an azaheteroaryl ring, pharmaceutically acceptable salts thereof, drug delivery reagents related thereto, pharmaceutical compositions comprising the drug delivery systems, and the use of the drug delivery systems as sustained release therapeutics.
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11389541
Date of patent
July 19, 2022
Patent application number
16591053
Date Filed
October 2, 2019
Patent citations
Patent primary examiner
Find more entities like US Patent 11389541 Sustained delivery of angiopoetin-like 3 polypeptides
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
